Complex immune correlates of protection in HIV-1 vaccine efficacy trials

被引:83
|
作者
Tomaras, Georgia D. [1 ,2 ,3 ]
Plotkin, Stanley A. [4 ,5 ]
机构
[1] Duke Human Vaccine Inst, Dept Surg, Durham, NC USA
[2] Duke Human Vaccine Inst, Dept Immunol, Durham, NC USA
[3] Duke Human Vaccine Inst, Dept Mol Genet & Microbiol, Durham, NC USA
[4] Vaxconsult, Doylestown, PA USA
[5] Univ Penn, Sch Med, Philadelphia, PA 19104 USA
基金
比尔及梅琳达.盖茨基金会; 美国国家卫生研究院;
关键词
antibodies; cellular; complex immune correlate; correlate of decreased HIV-1 risk; correlates of protection; HIV; humoral; immunity; sieve analysis; vaccination; TEST-OF-CONCEPT; DEPENDENT CELLULAR CYTOTOXICITY; IMMUNODEFICIENCY-VIRUS TYPE-1; LINKED-IMMUNOSORBENT-ASSAY; HUMAN MONOCLONAL-ANTIBODY; HERPES-ZOSTER VACCINE; CD4(+) T-CELLS; TERM-FOLLOW-UP; DOUBLE-BLIND; VIRION CAPTURE;
D O I
10.1111/imr.12514
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Development of an efficacious HIV-1 vaccine is a major priority for improving human health worldwide. Vaccine-mediated protection against human pathogens can be achieved through elicitation of protective innate, humoral, and cellular responses. Identification of specific immune responses responsible for pathogen protection enables vaccine development and provides insights into host defenses against pathogens and the immunological mechanisms that most effectively fight infection. Defining immunological correlates of transmission risk in preclinical and clinical HIV-1 vaccine trials has moved the HIV-1 vaccine development field forward and directed new candidate vaccine development. Immune correlate studies are providing novel hypotheses about immunological mechanisms that may be responsible for preventing HIV-1 acquisition. Recent results from HIV-1 immune correlates work has demonstrated that there are multiple types of immune responses that together, comprise an immune correlatethus implicating polyfunctional immune control of HIV-1 transmission. An in depth understanding of these complex immunological mechanisms of protection against HIV-1 will accelerate the development of an efficacious HIV-1 vaccine.
引用
收藏
页码:245 / 261
页数:17
相关论文
共 50 条
  • [31] HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers
    McFarland, Elizabeth J.
    Johnson, Daniel C.
    Muresan, Petronella
    Fenton, Terence
    Tomaras, Georgia D.
    McNamara, James
    Read, Jennifer S.
    Douglas, Steven D.
    Deville, Jaime
    Gurwith, Marc
    Gurunathan, Sanjay
    Lambert, John S.
    [J]. AIDS, 2006, 20 (11) : 1481 - 1489
  • [32] In vitro correlates of HIV-2-mediated HIV-1 protection
    Kokkotou, EG
    Sankalé, JL
    Mani, I
    Guèye-Ndiaye, A
    Schwartz, D
    Essex, ME
    Mboup, S
    Kanki, PJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (12) : 6797 - 6802
  • [33] Correlates of protection and HIV vaccine development
    Akpogheneta, Onome
    [J]. LANCET INFECTIOUS DISEASES, 2011, 11 (11): : 814 - 815
  • [34] Simulation studies of phase III clinical trials to test the efficacy of a candidate HIV-1 vaccine
    Desai, KN
    Boily, MC
    Masse, BR
    Alary, M
    Anderson, RM
    [J]. EPIDEMIOLOGY AND INFECTION, 1999, 123 (01): : 65 - 88
  • [35] Correlates of COVID-19 mRNA vaccine humoral immune responses in men living with HIV-1
    Tuttle, Dylan J.
    Castanha, Priscila M. S.
    Nasser, Amro
    Wilkins, Maris S.
    Cuff, Deirdre E.
    Chhibbar, Prabal
    Sluis-Cremer, Nicolas P.
    Das, Jishnu
    Mailliard, Robbie B.
    Rinaldo, Charles R.
    Marques, Ernesto T. A.
    [J]. JOURNAL OF IMMUNOLOGY, 2023, 210 (01):
  • [36] PedVacc Infant HIV-1 Vaccine Trials: First Stage Towards a Vaccine Against Breast Milk Transmission of HIV-1
    Hanke, T.
    Flanagan, K.
    Jaoko, W.
    John-Stewart, G.
    Reilly, M.
    Payne, B.
    Afolabi, M.
    Ambler, G.
    Black, A.
    Borthwick, N.
    Gichuhi, C.
    Mundia, M.
    Ndure, J.
    Njuguna, I.
    Osanya, J.
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2011, 27 (10) : A72 - A72
  • [37] Provision of treatment in HIV-1 vaccine trials in developing countries
    Fitzgerald, DW
    Pape, JW
    Wasserheit, JN
    Counts, GW
    Corey, L
    [J]. LANCET, 2003, 362 (9388): : 993 - 994
  • [38] Identifying barriers to participation in prophylactic HIV-1 vaccine trials
    Peters, BS
    [J]. INTERNATIONAL JOURNAL OF STD & AIDS, 2006, 17 (02) : 73 - 73
  • [39] Prophylactic HIV-1 vaccine trials: past, present, and future
    Nkolola, Joseph P.
    Barouch, Dan H.
    [J]. LANCET HIV, 2024, 11 (02): : e117 - e124
  • [40] CTL RESPONSES IN HIV-1 UNINFECTED VOLUNTEERS PARTICIPATING IN PHASE-1 HIV-1 VACCINE TRIALS
    MCELRATH, MJ
    COREY, L
    RABIN, M
    HOFFMAN, M
    KLUCKING, S
    GREENBERG, PD
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 82 - 82